MOUNTAIN VIEW, Calif., Nov. 10, 2011 /PRNewswire/ --
Highlights from Avanafil Development Program Include:
VIVUS, Inc. (NASDAQ: VVUS) today announced that multiple abstracts will be presented at the Sexual Medicine Society of North America (SMSNA) on November 12, 2011 in Las Vegas, NV. The SMSNA is the largest gathering of medical professionals specializing in sexual dysfunction and treatment in North America.
The specific abstracts to be presented on November 12, 2011 include:
A moderated poster presentation by Wayne Hellstrom, MD, Professor of Urology and Chief of Andrology (male infertility and sexual dysfunction) at Tulane University School of Medicine, entitled:
Onset of Action and Time to Efficacy of Avanafil, a Novel, Rapid-Onset PDE5 Inhibitor in Men with Mild to Severe Erectile Dysfunction: Data From Phase 2 and Phase 3 Clinical TrialsDr. Hellstrom will report that in the largest, randomized, phase 3 study of avanafil (TA-301), 67% of the patients who attempted intercourse within 15 minutes of dosing were successful.
A moderated poster presentation by Run Wang, MD, Associate Professor of Surgery in the Division of Urology and holder of the Cecil M. Crigler, MD Chair in Urology at the University of Texas Health Science Center in Houston, entitled:
Avanafil, a Highly Selective Phosphodiesterase Type 5 Inhibitor for the Treatment of Erectile Dysfunction: Selectivity for Eleven PDE Isozymes, in Comparison With Sildenafil, Tadalafil and VardenafilDr. Wang will share his in-vitro analysis of avanafil selectivity for eleven PDE isozymes, in compari
|SOURCE VIVUS, Inc.|
Copyright©2010 PR Newswire.
All rights reserved